What’s Next? How to Approach Treatment Resistant Depression - Live Webinar on December 11, 2024 10AM ET
Learn about treatment-resistant depression (TRD) and the latest therapies, including esketamine. This course offers comprehensive training for healthcare professionals to confidently manage TRD patients for optimal outcomes.
About this webinar
Healthcare professionals often encounter patients with depression in their practice. Despite using first-line treatments, a significant portion of these patients may not respond, leading to a phenomenon known as treatment-resistant depression (TRD). This complex issue presents a unique challenge to providers, often leaving them uncertain of the next steps. Coupled with the introduction of new therapies like esketamine and others that require proper understanding for effective use, there is a clear need for healthcare professionals to be updated on the latest treatment options and strategies for TRD. This course is designed to address this need, providing comprehensive training to equip healthcare providers with the knowledge and skills to confidently manage patients with TRD, ensuring optimal outcomes.
At the conclusion of this continuing education activity, the participant will be able to:
Define treatment resistant depression
Discuss augmentation strategies when working with depression
Review other treatment options for resistant patients
Reference current research surrounding the treatment of resistant depression
Instructors
Bennett Doughty earned his PhD degree from the University of Connecticut School of Pharmacy in 2016. Following graduation, Doughty completed two years of residency training at the VA Connecticut Healthcare System in West Haven, Conn., specializing in psychiatric pharmacy. He joined the Binghamton School of Pharmacy and Pharmaceutical Sciences in 2018 as a clinical assistant professor in psychiatry/neurology within the Department of Pharmacy Practice. He currently is the treasurer/secretary of the New York State chapter of the American College of Clinical Pharmacy (ACCP) and serves on the College of Psychiatric and Neurologic Pharmacists (CPNP) National Consumer Relations Board. His research interests primarily focus on the engagement of patients in substance use disorder treatment, particularly within the opioid epidemic.